Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor

Journal of Gastroenterology

Volumn 37, Issue 10, 2002, Pages 863-867

  Matsubayashi, Hiroyuki ^a   Takagaki, Shinichi ^a   Otsubo, Takao ^a   Iiri, Takao ^a   Kobayashi, Yuka ^a   Yokota, Takashi ^a   Shichjo, Kimitoshi ^a   Iwafuchi, Mitsuya ^b   Kijima, Hiroshi ^c  

^a Tachikawa General Hospital   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Interleukin (IL) 2 receptor; Malignant lymphoma; Pancreas; T cell

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ABDOMINAL DISEASE; AGED; ANOREXIA; ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENDOCRINE TUMOR; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FAMILY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LYMPHADENOPATHY; MALE; MIXED CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PANCREAS DUCT; PANCREAS TUMOR; PARAAORTIC LYMPH NODE; PATIENT ATTITUDE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; T CELL LYMPHOMA;

AGED; AGED, 80 AND OVER; HUMANS; LYMPHOMA, T-CELL; MALE; PANCREATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0036812944     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350200143     Document Type: Article

References (53)

1. Freedman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-60.
2. Webb TH, Lillemoe KD, Pitt HA, Jones RJ, Cameron JL. Pancreatic lymphoma. Is surgery mandatory for diagnosis or treatment? Ann Surg 1989;209:25-30.
3. Baylor SM, Berg JW. Cross-classification and survival characteristics of 5000 cases of cancer of the pancreas. J Surg Oncol 1973;5:335-8.
4. Costello P, Duszlak EJ Jr, Kane RA, Lee RG, Clouse ME. Peripancreatic lymph node enlargement in Hodgkin's disease, non-Hodgkin's lymphoma, and pancreatic carcinoma. J Comput Tomogr 1984;8:1-11.
5. Prayer L, Schurawitzki H, Mallek R, Mostbeck G. CT in pancreatic involvement of non-Hodgkin lymphoma. Acta Radiol 1992;33:123-7.
6. Teefey SA, Stephens DH, Sheedy II PF. CT appearance of primary pancreatic lymphoma. Gastrointest Radiol 1986;11:41-3.
7. Beers BV, Lalonde L, Soyer P, Grandin C, Trigaux JP, DeRonde T, et al. Dynamic CT in pancreatic lymphoma. J Comput Assist Tomogr 1993;17:94-7.
8. Ackerman NB, Aust JC, Brendenberg CE, Hanson VA Jr, Rongers LS. Problems in differentiating between pancreatic lymphoma and anaplastic carcinoma and their management. Ann Surg 1976;184:705-8.
9. Tuchek JM, de Jong SA, Pickleman J. Diagnosis, surgical intervention, and prognosis of primary pancreatic lymphoma. Am Surg 1993;59:513-8.
10. Brown PC, Hart MJ, White TT. Pancreatic lymphoma, diagnosis and management. Int J Pancreatol 1987;2:93-9.
11. Rosenberg SA, Diamond HD, Jaslowitz B, Craver LF. Lymphosarcoma: a review of 1269 cases. Medicine 1961;61:31-84.
12. Dawson IMP, Cornes JS, Moeson BC. Primary lymphoid tumors of the intestinal tract: report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961;49:80-9.
13. Behrns KE, Sarr MG, Strickler JG. Pancreatic lymphoma: is it a surgical disease? Pancreas 1994;9:662-7.
14. Matsubayashi H, Watanabe H, Ajioka Y, Nishikura K, Yamano M, Seki T, Saito T. Different amounts of K-ras mutant epithelial cells in pancreatic carcinoma and mass-forming pancreatitis. Pancreas 2000;21:77-85.
15. Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol 1990;7:37-47.
16. Ohana M, Okazaki K, Hajiro K, Kobashi Y. Multiple pancreatic masses associated with autoimmunity. Am J Gastroenterol 1998;93:99-102.
17. Horiuchi A, Kaneko T, Yamamura N, Nagata A, Nakamura T, Akamatsu T, et al. Autoimmune chronic pancreatitis simulating pancreatic lymphoma. Am J Gastroenterol 1996;91:2607-9.
18. Okazaki K, Uchida K, Ohana M, Nakase H, Uose, S, Inai M, et al. Autoimmune-related pancreatitis is associated with auto-antibododies and a Th1/Th2-type cellular immune response. Gastroenterology 2000;118:573-81.
19. Rumessen JJ, Marner B, Pedersen NT, Permin H. Autoantibodies in chronic pancreatitis. Scand J Gastroenterol 1985;20:966-70.
20. Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmuneabnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995;40:1561-8.
21. Nishimori I, Yamamoto, Y, Okazaki K, Morita M, Onodera M, Kino J, et al. Identification of autoantibodies to a pancreatic antigen in patients with idiopathic chronic pancreatitis and Sjogren's syndrome. Pancreas 1994;9:374-81.
22. Irie H, Honda H, Baba S, Kuroiwa T, Yoshimitsu K, Tajima T, et al. Autoimmune pancreatitis: CT and MR characteristics. AJR Am J Roentgenol 1998;170:1323-7.
23. Ito T, Nakano I, Koyanagi S, Miyahara T, Migita Y, Ogoshi K, et al. Autoimmune pancreatitis as a new clinical entity. Three cases of autoimmune pancreatitis with effective steroid therapy. Dig Dis Sci 1997;42:1458-68.
24. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
25. Stasi R, Zinzani PL, Calieni P, Lauta VM, Damasio E, Dispensa E, et al. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Cancer 1994;74:1792-800.
26. Motokura T, Kobayashi Y, Fujita A, Nakamura Y, Taniguchi T, Uchimaru K, Asano S. Clinical significance of serial measurement of serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma. Leuk Lymphoma 1995;16:355-62.
27. Enbad G, Sundstrom C, Gronowitz S, Glimelius B. Serum levels of interleukin-2 (CD25) in patients with Hodgkin's disease, with special reference to age and prognosis. Ann Oncol 1995;6:64-70.
28. Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, et al. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease:outcome and clinical implications. Br J Cancer 1998;77:992-7.
29. Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, et al. Prognostic significance of serum level in non-Hodgkin's lymphoma: a single center study in Japan. Leuk Lymphoma 2000;37:151-6.
30. Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 2001;66:24-30.
31. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, Tomonaga M. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994;73:2753-8.
32. Pavlidis NA, Manoussakis MN, Germanidis GS, Moutsopoulos HM. Serum-soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Med Pediatr Oncol 1992;20:26-31.
33. Zwierzine H, Herold M, Schollenberger S, Geissler D, Schmalz F. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF. Br J Haematol 1991;79:438-43.
34. Honda M, Kitamura K, Matsuda K, Yokota Y, Yamamoto N, Mitsuyasu JC, et al. Soluble IL-2 receptor in AIDS. J Immunol 1989;142:4248-55.
35. Szeimies RM, Rueff F, Kaudewitz P. Soluble interleukin-2 receptor serum levels in mycosis fungoides. Correlation with clinical stage. Cancer 1992;70:2338-41.
36. Brown AE, Rieder KT, Webster HK. Prolonged elevation of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis 1989;139:1036-8.
37. Lawrence EC, Berger MB, Brousseau KP, Rodriguez TM, Siegel SJ, Kurman CC, Nelson DL. Elevated serum levels of soluble interleukin-2 receptor in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia. Sarcoidosis 1987; 4:87.
38. Colvin RB, Fuller TC, Mackeen L, Kung PC, Ip SH, Cosimi AB. Plasma interleukin-2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol 1987;43:273-6.
39. Semenzato G, Bamnara LM, Biasi D, Frigo A, Vinante F, Zuppini B, et al. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 1988;8:447-52.
40. Campen DH, Horwitz DA, Quismorio FP Jr, Ehresmann GR, Martin WJ. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988;31:1358-64.
41. Prummel MF, Wiersinga WM, Gaag RVD, Muurits MP, Koornneef L. Soluble IL-2 receptor levels in patients with Graves ophthalmopathy. Clin Exp Immunol 1992;88:405-9.
42. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr. Soluble interleukin 2 receptors in patients with systemic sclerosis. Arthritis Rheum 1990;33:375-80.
43. Lobo-Yeo A, Mieli-Vergani G, Mowat AP, Vergani D. Soluble interleukin 2 receptors in autoimmune chronic active hepatitis. Gut 1990;31:690-3.
44. Matsuura T, West GA, Klein JS, Ferraris L, Fiocchi C. Soluble interleukin 2 and CD8 and CD4 receptors in inflammatory bowel disease. Gastroenterology 1992;102:2006-14.
45. Kapp A, Piskorski A, Schopf E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol 1988;119:707-10.
46. Teodorczyk-Injeyan JA, McRitchie DI, Peters WJ, Lalani S, Girotti MJ. Expression and secretion of IL-2 receptor in trauma patients. Ann Surg 1990;212:202-8.
47. Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, Tancini G. The biological significance of soluble interleukin-2 receptor in solid tumors. Eur J Cancer 1990;26:33-6.
48. Pezzilli R, Billi P, Gullo L, Beltrandi E, Maldini M, Mancini R, et al. Behavior of serum soluble interleukin-2 receptor, soluble CD8 and soluble CD4 in the early phases of acute pancreatitis. Digestion 1994;55:268-73.
49. Salomone T, Boni P, Serra C, Morselli-Labate AM, DiGioia AL, Romboli M, Guariento A. The soluble interleukin-2 receptor, peripheral blood and reticulocyte fractions in acute pancreatitis. Int J Pancreatol 1996;20:197-203.
50. Mayer J, Rau B, Gansauge F, Beger HG. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications. Gut 2000;47:546-52.
51. Kylanpaa-Back ML, Takala A, Kemppainen EA, Poulakkainen PA, Leppäniemi AK, Karonen SL, et al. Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis. Crit Care Med 2001;29:63-9.
52. Pezzilli R, Billi P, Beltrandi E, Mancini R, Casadei-Maldini M, Casadei R, et al. Serum soluble interleukin-2 receptor in pancreatic cancer and chronic pancreatitis. Ital J Gastroenterol 1994;26:137-40.
53. Rabitti PG, Pacelli L, Uomo G, Laccetti M, Spada OA, Esposito G, Visconti M. Soluble interleukin-2 receptor: a new marker in pancreatic adenocarcinoma? Minerva Gastroenterol Dietol 1994; 40:101-3.